Welcome to our dedicated page for Avalon Globocare news (Ticker: ALBT), a resource for investors and traders seeking the latest updates and insights on Avalon Globocare stock.
Avalon Globocare Corp (ALBT) delivers innovative solutions at the intersection of biotechnology and healthcare services. This dedicated news hub provides investors and industry observers with essential updates on the company’s advancements in cell-based therapies, precision diagnostics, and healthcare facility management.
Access authoritative reports covering clinical milestones, financial disclosures, and strategic partnerships. Our curated collection includes press releases on therapeutic developments, regulatory updates, and operational expansions within ALBT’s dual business segments: real property management and medical consulting services.
Key areas of coverage include progress in early cancer detection systems, regenerative medicine research, and healthcare infrastructure developments. All content is verified for accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to ALBT’s latest announcements. Check regularly for updates reflecting the company’s role in advancing biotechnological innovation and patient care solutions.
Avalon GloboCare Corp. (NASDAQ: ALBT) has launched online sales of the KetoAir™ breathalyzer in the U.S. at www.ketoair.us. This FDA-registered device features Hot App shareable technology with AI-enabled software for ketogenic health management. The KetoAir™ breathalyzer uses nano-sensor-based technology and AI algorithms to assess ketosis status and record diet and exercise details via its app.
The device offers personalized nutritional and exercise recommendations through its AI nutritionist feature. Avalon has exclusive distributorship rights for KetoAir™ in North America, South America, EU, and the UK. To celebrate the launch, Avalon is offering a special introductory price of $199 (regular $249) with an additional 20% discount using coupon code 'intro20'.
Avalon GloboCare announced the successful U.S. launch of its KetoAir™ breathalyzer at the Hack Your Health by KetoCon 2024 Conference. The event, held from May 31 to June 2, 2024, in Austin, Texas, attracted diverse stakeholders such as doctors, health coaches, and retailers. The device, registered with the FDA (No. 3026284320), uses AI-enabled software and nano-sensor technology to monitor ketosis through a non-invasive breath test. Avalon introduced a Zero to Keto program and expects retail sales to begin later this month, with purchases available exclusively at KetoAir.com.
Avalon GloboCare (NASDAQ: ALBT) announced that it has received a notice from Nasdaq on May 22, 2024, stating that the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to its failure to file the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024.
The notice does not affect the immediate listing or trading of Avalon's common stock. The company has until July 22, 2024, to submit a plan to regain compliance. If accepted, Nasdaq may allow until November 18, 2024, for Avalon to file the report and regain compliance. Avalon is working to finalize and file the report promptly.
FAQ
What is the current stock price of Avalon Globocare (ALBT)?
What is the market cap of Avalon Globocare (ALBT)?
